Highlights
- BlueScope Steel (ASX:BSL) shares surge nearly 11% following strong earnings report.
- Earnings before interest and tax (EBIT) outperforms estimates despite a 57% year-over-year decline.
- Cost-saving initiatives and potential upside in earnings outlook provide a positive outlook.
BlueScope Steel (ASX:BSL) witnessed a sharp rally in its stock price, climbing nearly 11% to $24.75 in early trading. The surge came after Australia’s largest steel producer posted earnings near the upper end of its guidance range, surpassing market expectations.
For the first half of fiscal year 2025, BlueScope Steel reported an underlying EBIT of $308.8 million. While this reflected a 57% decline compared to the previous year, it still exceeded Visible Alpha estimates by 5%. The strong performance was primarily driven by robust average selling prices (ASP), which contributed to better-than-anticipated results.
Despite the impressive first-half performance, the company's guidance for the second half of the fiscal year suggests an EBIT range of $360 million to $430 million, slightly below market consensus. However, analysts note that if current market conditions remain stable, there could be an additional upside of approximately $70 million to EBIT, driven by spot price spreads.
One of the key aspects analysts are closely watching is BlueScope Steel’s cash flow. While weaker-than-expected cash flow was noted, the company continues to maintain a strong financial position with a net cash status. Additionally, management remains focused on optimizing working capital and implementing a $200 million cost-reduction program, which is expected to support future earnings.
The steelmaker’s ability to navigate market challenges while maintaining profitability highlights its resilience in the industry. With strategic cost management efforts underway and a potential earnings upside, the company remains well-positioned for the coming quarters. The latest earnings performance has instilled confidence among investors, reflected in the significant jump in its stock price.